3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Osteosarcoma
3
Neuroblastoma
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Stomach Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Nerve Sheath Neoplasms
1
Myoepithelioma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Giant Cell Tumor of Bone
1
Desmoplastic Small Round Cell Tumor
1
Chordoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Ascites
1
Adenocarcinoma
1
Interventions
Oxaliplatin
42
Fluorouracil
27
Capecitabine
24
pembrolizumab
21
S 1 (combination)
19
Paclitaxel
19
Leucovorin
16
Nivolumab
13
Docetaxel
13
sintilimab
12
Drug Therapy
12
Trastuzumab
11
tislelizumab
10
Cisplatin
10
Irinotecan
9
Bevacizumab
8
trastuzumab deruxtecan
7
spartalizumab
7
XELOX
7
Surgical Procedures, Operative
7
Radiotherapy
7
Hyperthermic Intraperitoneal Chemotherapy
7
Biopsy
7
fludarabine
6
disitamab vedotin
6
Cyclophosphamide
6
lenvatinib
5
apatinib
5
Specimen Handling
5
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Stomach Neoplasms
×
Zoledronic Acid
×
Clear all
NCT06759064
2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2
Recruiting
24 enrolled